Following the idea of targeting MLK1 as a therapeutic agent in treating prostate cancers, an earlier study in rats using a potent inhibitor of the MLK family showed that inhibiting MLKs did not affect either the survival or proliferation status of normal prostate epithelium in response to modulation of AR functions [31]. The gene discussed is MAP3K13; the disease is prostate carcinoma.